VIEWPOINTS

Nathan McCutcheon shares highlights of Qpex Biopharma’s acquisition by Shionogi

Shots: Nathan McCutcheon, President, and Chief Executive Officer of Shionogi, shares the highlights of the recent acquisition of Qpex Biopharma by Shionogi Nathan believes that Qpex’s specialized expertise and extensive experience in chemistry and molecular design are sure to strengthen and be useful for the combined antibiotic pipeline The acquisition provides Shionogi exclusive development, manufacturing,…

October 16, 2023

Robert Connelly shares the highlights of the post-merger between Elicio Therapeutics & Angion Biomedica Corp.

Shots: Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies Robert recapitulates data presented at ASCO…

October 9, 2023

Samantha Kerr shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+)

Shots: Samantha Kerr, Chief Scientific Officer, Merz Aesthetics shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+) Samantha says, for Belotero Balance (+), Merz Aesthetics has already submitted the data as a supplemental Premarket Approval Application (sPMA) with the FDA and plans to submit the data as…

October 5, 2023

Sergey Yurasov Shares Insights on Initial Dose Escalation Data of BDTX-1535 for the Treatment of Non-Small Cell Lung Cancer Patients

Shots: During the initial part of conversation, Sergey discussed details about the BDTX-1535 and the trial design of the P-I study where 1535 is being investigated in NSCLC and GBM patients He then discussed the insights drawn from the first 51 patients recruited in the dose escalation part of the P-I study In the final…

October 3, 2023

Ruud Dobber Shares Insights from RWE Data from the REVEAL-CKD Presented at the ERA-EDTA’23

Shots: Ruud talked about the key findings from the new RWE data at ERA-EDTA'23 which demonstrated the staggeringly low rate of diagnosis in chronic kidney disease (CKD) He then discussed the risk factors of CKD and the urgent need to act on the growing global burden of CKD and how this disease is impacting the…

September 25, 2023

The US FDA OTC Approval of Topical Gel for Erectile Dysfunction: Insights from Ken James

Shots: Ken gave a brief overview of the OTC marketing approval of Eroxon (MED3000) by the US FDA. He also talked about Eroxon’s mechanism of action and how it helps to treat erectile dysfunction Later, he discussed the study design and results obtained from the clinical trial based on which the approval was granted. In…

September 21, 2023

Grant Kim Shares His Views from the Data Showing the World’s First Dual-Chamber Leadless Pacemaker Study Achieving All Three Primary Endpoints

Shots: Grant started by highlighting the characteristics of the AVEIR DR leadless pacemaker and this pacemaker is an effective treatment for people with slower-than-normal heart rhythms He discussed the AVEIR™ DR i2i™ IDE study's design and outcomes, which assessed the safety and performance of the world's first dual-chamber leadless pacemaker. The study effectively met all…

September 19, 2023

Simon Portsmouth Shares Insights from P-III Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Shots: Simon spoke about the enrollment of the first participant in Japan in the P-III (SCORPIO-PEP) study to evaluate the safety and efficacy of Ensitrelvir for the prevention of symptomatic SARS-CoV-2 infection He mentioned how this study will supplement data from the pivotal SCORPIO-SR trial's P-III segment which showed ensitrelvir's effectiveness in treating mild-to-moderate COVID-19…

September 18, 2023

VIEWPOINTS_Dr. Christopher Piorkowski_2023

Dr. Christopher Piorkowski Shares His Views on the US FDA Approval of TactiFlex Ablation Catheter to Treat Abnormal Heart Rhythm

Shots: Christopher started by highlighting the working of the TactiFlex Ablation Catheter and how it can be used for the treatment of patients with Atrial Fibrillation He also talked about the study design and the key findings from the TactiFlex AF IDE trial. He later gave a comparative view of the TactiFlex catheter vs. conventional…

September 11, 2023

Kyle Forcier Shares His Views from Model N’s 2023 Product Updates for Pharma

Shots: Kyle started by giving a brief introduction to Model N’s Spring 2023 product release for life sciences and high-tech customers and discussed its key features He then spoke about the challenges faced by the pharmaceutical industry due to duplicate discounts and how Model N’s 340B Vigilance Solution can address these challenges The interview shows…

September 7, 2023